HUP0402080A3 - Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease - Google Patents

Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease

Info

Publication number
HUP0402080A3
HUP0402080A3 HU0402080A HUP0402080A HUP0402080A3 HU P0402080 A3 HUP0402080 A3 HU P0402080A3 HU 0402080 A HU0402080 A HU 0402080A HU P0402080 A HUP0402080 A HU P0402080A HU P0402080 A3 HUP0402080 A3 HU P0402080A3
Authority
HU
Hungary
Prior art keywords
cannabionid
medicament
preparation
treatment
receptor agonists
Prior art date
Application number
HU0402080A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUP0402080A2 publication Critical patent/HUP0402080A2/hu
Publication of HUP0402080A3 publication Critical patent/HUP0402080A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0402080A 2001-11-23 2002-11-20 Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease HUP0402080A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
HUP0402080A2 HUP0402080A2 (hu) 2005-02-28
HUP0402080A3 true HUP0402080A3 (en) 2008-03-28

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402080A HUP0402080A3 (en) 2001-11-23 2002-11-20 Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease

Country Status (20)

Country Link
US (1) US7358245B2 (https=)
EP (1) EP1453497A1 (https=)
JP (1) JP2005511632A (https=)
KR (1) KR20050044582A (https=)
CN (1) CN1610542A (https=)
AR (1) AR037299A1 (https=)
AU (1) AU2002353700A1 (https=)
BR (1) BR0214319A (https=)
CA (1) CA2466916A1 (https=)
HU (1) HUP0402080A3 (https=)
IL (1) IL161748A0 (https=)
IS (1) IS7272A (https=)
MX (1) MXPA04004774A (https=)
NO (1) NO20042613L (https=)
NZ (1) NZ532844A (https=)
PL (1) PL369402A1 (https=)
RU (1) RU2280443C2 (https=)
TW (1) TW200407110A (https=)
WO (1) WO2003043619A1 (https=)
ZA (1) ZA200403785B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
US8628796B2 (en) * 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
EP2205240A1 (en) * 2007-10-02 2010-07-14 Ariel-University Research And Development Company, Ltd. Endocannabinoids for enhancing growth and development in infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
EP0887340A4 (en) * 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
AU6690001A (en) * 2000-06-15 2001-12-24 Schering Corp Thrombin receptor antagonists
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
JP2005511632A (ja) 2005-04-28
CN1610542A (zh) 2005-04-27
CA2466916A1 (en) 2003-05-30
BR0214319A (pt) 2004-11-03
IS7272A (is) 2004-05-19
US20040266861A1 (en) 2004-12-30
RU2280443C2 (ru) 2006-07-27
WO2003043619A1 (en) 2003-05-30
EP1453497A1 (en) 2004-09-08
HUP0402080A2 (hu) 2005-02-28
PL369402A1 (en) 2005-04-18
WO2003043619A8 (en) 2005-03-17
AR037299A1 (es) 2004-11-03
RU2004114843A (ru) 2005-05-27
US7358245B2 (en) 2008-04-15
NZ532844A (en) 2005-12-23
IL161748A0 (en) 2005-11-20
TW200407110A (en) 2004-05-16
ZA200403785B (en) 2005-05-19
AU2002353700A1 (en) 2003-06-10
KR20050044582A (ko) 2005-05-12
MXPA04004774A (es) 2004-07-30
NO20042613L (no) 2004-08-13

Similar Documents

Publication Publication Date Title
PL370818A1 (en) Dosage form for treatment of diabetes mellitus
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB0207460D0 (en) A device for the picture-proving diagnosis of tissue
GB0228897D0 (en) Improved oral medicine dispenser
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
HUP0402080A3 (en) Use of cannabionid receptor agonists for the preparation of a medicament for treatment of gastroesophageal reflux disease
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
IL206566A0 (en) Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
IL150290A (en) Use of mirtazapine for preparation of a medicament for the treatment of sleep disorders
EP1474449A4 (en) HUMAN ANTIBODY FOR USE AS A THERAPEUTIC AGENT AGAINST VACCINIA BZW. SMALLPOX
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
HUP0401599A3 (en) Extended release oral dosage form
AP2004003087A0 (en) Oral dosage form for controlled drug release
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
AU2562501A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
EP1449547A4 (en) EVACUATION TOOL FOR MEDICAL CARE
GB0209254D0 (en) Preparation for the relief of disease
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0128628D0 (en) Disease treatment
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
HK1067309A (en) Use for the treatment of gastroesophageal reflux disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees